Standard neoadjuvant therapy — Competitive Intelligence Brief

Standard neoadjuvant therapy (Standard neoadjuvant therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy. Area: Oncology.

phase 3 Chemotherapy Oncology Small molecule

Target snapshot

Standard neoadjuvant therapy (Standard neoadjuvant therapy) — Shanghai Zhongshan Hospital. Standard neoadjuvant therapy involves administering a combination of chemotherapy drugs before surgery to reduce tumor size and improve surgical outcomes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard neoadjuvant therapy TARGET	Standard neoadjuvant therapy	Shanghai Zhongshan Hospital	phase 3	Chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Pegylated liposomal doxorubicin hydrochloride	Pegylated liposomal doxorubicin hydrochloride	M.D. Anderson Cancer Center	marketed	Anthracycline chemotherapy (liposomal formulation)	Topoisomerase II, DNA
DSP	DSP	Taiwan Liposome Company	marketed	Liposomal anthracycline chemotherapy	Topoisomerase II
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
Gemcitabine-Cisplatin chemotherapy	Gemcitabine-Cisplatin chemotherapy	Simcere Pharmaceutical Co., Ltd	marketed	Chemotherapy combination (nucleoside analog + platinum agent)	DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy class)

1. University Hospital, Rouen · 2 drugs in this class
2. Sun Yat-sen University · 2 drugs in this class
3. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
4. Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
5. Delcath Systems Inc. · 1 drug in this class
6. Ludwig-Maximilians - University of Munich · 1 drug in this class
7. Prof. Dr. med. Claus Rödel · 1 drug in this class
8. Prothena Biosciences Ltd. · 1 drug in this class
9. Seoul National University Hospital · 1 drug in this class
10. Shanghai Zhongshan Hospital · 1 drug in this class